Abiraterone could halve risk of prostate cancer death for some patients

24 December 2021

Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading, could halve the risk of death from the disease, according to a trial co-led by Professor Gert Attard (UCL Cancer Institute).